Table 3 Population characteristics of included studies
Author | Year | Study Design | Procedure | Level of Evidence | Number of patients/hips | Sex M/F | Age in years ± SD (Range) | Follow up period months ± SD (Range) |
|---|---|---|---|---|---|---|---|---|
Schroeder et al [41] | 2016 | Prospective case series | ACT | 4 | 20/21 | 16/4 | 33 (22–49) | 12.05 (6–24) |
Krueger et al [42] | 2021 | Retrospective case series | ACT | 4 | 36/36 | 31/5 | 32.9 (18–49) | 29.9 (24–42) |
Bretschneider et al [39] | 2019 | Prospective case series | ACT | 4 | 21/21 | 17/4 | 32.3 ± 10 (20–53) | 12 |
Thier et al [43] | 2017 | Retrospective case series | ACT | 4 | 29/29 | 27/2 | 30.3 ± 6.9 | 19 (6–24) |
Krueger et al [44] | 2018 | Retrospective case series | ACT | 4 | 32/32 | 28/4 | 32 (18–49) | 35.5 (24–49) |
Mancini, Fontana [32] | 2014 | Retrospective Case control series | ACT | 3 | 26/26 | 12/14 | 36 ± 9.3 | 60 |
AMIC | 3 | 31/31 | 13/18 | 36.4 ± 10.3 | 60 | |||
Briem et al [45] | 2024 | Retrospective case series | AMIC | 4 | 11/12 | 10/1 | 26.8 (5.0) | 74 ± 5.2 |
Thorey et al [46] | 2020 | Retrospective case series | AMIC | 4 | 62/62 | 28/34 | 34.3 ± 5.4 (18–44) | 25 (24–27) |
de Girolamo et al [47] | 2018 | Retrospective case series | AMIC | 3 | 59/59 | 27/32 | 39.3 (18–55) | 96 |
Villarrubia et al [48] | 2022 | Retrospective case series | AMIC | 4 | 25/28 | 19/6 | 40.5 ± 7.1 (25–55) | 29 (24–48) |
Fontana [49] | 2016 | Retrospective, non-randomised study | AMIC | 4 | 201/201 | 84/117 | 36.4 ± 10.3 | 48 |
Fontana and de Girolamo [50] | 2015 | Retrospective, non-randomised study | AMIC | 3 | 70/70 | 36/34 | 39.1 (18–55) | 60 |